Currently priced at approximately $80.53 per share, Haemonetics (HAE) is trading roughly 7.6% below its 52-week ...

Loomis Sayles, an investment management company, released its “Small Cap Value Fund” third-quarter 2025 investor letter. A ...

Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q3 2025 investor letter. A copy of ...

Investors in Haemonetics Corporation (NYSE:HAE) had a good week, as its shares rose 6.8% to close at US$68.19 following the release of its annual results. Haemonetics reported US$1.4b in revenue, ...

Haemonetics’ CEO, Chris Simon, highlighted strategic execution and value creation, emphasizing the company’s focus on high-growth, high-margin products. Looking ahead, Haemonetics forecasts a decline ...

Blood products company Haemonetics (NYSE:HAE). will be reporting results tomorrow before market open. Here’s what you need to know. Haemonetics missed analysts’ revenue expectations by 1.3% last ...

9 analysts have shared their evaluations of Haemonetics (NYSE:HAE) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

BOSTON, March 2, 2021 /PRNewswire/ -- Haemonetics Corporation ("Haemonetics") (NYSE: HAE) today announced the pricing of its offering of $435,000,000 aggregate principal amount of 0.00% Convertible ...

BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the ...

Haemonetics has outperformed the medical device sector, with shares up 7% on very strong revenue growth in plasma collection and good margin leverage. The recent acquisition of OpSens expands ...

We believe that the stock price of Haemonetics (NYSE: HAE), best known for its blood and plasma supplies and services, is undervalued at current levels of $63. HAE stock is down 27% from the levels of ...

The company broadly meets expectations for its Q2 2022 but trims its full-year guidance. Haemonetics booked revenue of $240 million for its second quarter of fiscal 2022, which was 15% higher on a ...